BR9808920A - Partìcula estável em formulações lìquidas - Google Patents

Partìcula estável em formulações lìquidas

Info

Publication number
BR9808920A
BR9808920A BR9808920-0A BR9808920A BR9808920A BR 9808920 A BR9808920 A BR 9808920A BR 9808920 A BR9808920 A BR 9808920A BR 9808920 A BR9808920 A BR 9808920A
Authority
BR
Brazil
Prior art keywords
microparticles
sugar glass
mannitol
liquid formulations
particularly stable
Prior art date
Application number
BR9808920-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Jaap Kampinga
Original Assignee
Quadrant Holdings Cambridge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10809442&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9808920(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Quadrant Holdings Cambridge filed Critical Quadrant Holdings Cambridge
Publication of BR9808920A publication Critical patent/BR9808920A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR9808920-0A 1997-03-18 1998-03-18 Partìcula estável em formulações lìquidas BR9808920A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9705588.3A GB9705588D0 (en) 1997-03-18 1997-03-18 Stable particle in liquid formulations
PCT/GB1998/000817 WO1998041188A2 (en) 1997-03-18 1998-03-18 Stable particle in liquid formulations

Publications (1)

Publication Number Publication Date
BR9808920A true BR9808920A (pt) 2000-08-01

Family

ID=10809442

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808920-0A BR9808920A (pt) 1997-03-18 1998-03-18 Partìcula estável em formulações lìquidas

Country Status (14)

Country Link
US (1) US6669963B1 (enExample)
EP (1) EP1007000B1 (enExample)
JP (1) JP2002504090A (enExample)
CN (1) CN1256626A (enExample)
AT (1) ATE325605T1 (enExample)
AU (1) AU722627B2 (enExample)
BR (1) BR9808920A (enExample)
CA (1) CA2293682C (enExample)
DE (1) DE69834495T2 (enExample)
EA (1) EA001873B1 (enExample)
GB (1) GB9705588D0 (enExample)
NO (1) NO994508L (enExample)
NZ (1) NZ337666A (enExample)
WO (1) WO1998041188A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10508744A (ja) 1994-09-22 1998-09-02 クオドラント ホールディングス ケンブリッジ リミテッド 運動競技の間の水分補給および栄養摂取の用途のための組成物ならびにその製造法
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
AU2945199A (en) * 1998-03-18 1999-10-11 Ronai, Peter Amorphous glasses for stabilising sensitive products
US6190701B1 (en) 1999-03-17 2001-02-20 Peter M. Ronai Composition and method for stable injectable liquids
US6102896A (en) * 1999-09-08 2000-08-15 Cambridge Biostability Limited Disposable injector device
DE19943491B4 (de) * 1999-09-10 2010-04-01 Südzucker AG Mannheim/Ochsenfurt Verbesserte Komprimate
WO2001037804A2 (en) * 1999-11-22 2001-05-31 Universal Preservation Technologies, Inc. Preservation and formulation of bioactive materials
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
GB0024271D0 (en) * 2000-09-25 2000-11-15 Colaco Camilo Improved methods and compositions for pulmonary delivery of actives
RU2259817C2 (ru) * 2000-10-13 2005-09-10 Кембридж Байостэбилити Лтд. Композиция для доставки стабильных инъецируемых жидкостей и способ доставки
PL360052A1 (en) * 2000-10-13 2004-09-06 Cambridge Biostability Ltd. Composition and method for stable injectable liquids
EP1452171B1 (en) * 2000-10-13 2009-12-02 Cambridge Biostability Limited Pharmaceutical liquid suspensions
WO2002032398A2 (en) * 2000-10-16 2002-04-25 Massachusetts Institute Of Technology Lipid-protein-sugar particles for drug delivery
US7153472B1 (en) 2000-11-22 2006-12-26 Quadrant Drug Delivery Limited Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
US6623762B2 (en) * 2001-02-16 2003-09-23 Cambridge Biostability Ltd. Composition and method for controlled release injections
FR2825276B1 (fr) * 2001-05-31 2004-11-26 Seppic Sa Adujvant d'immunite sous forme solide et vaccin le contenant
EP1418229B1 (en) * 2001-07-02 2009-04-22 Asahi Kasei Pharma Corporation Method of stabilizing alkaline phosphatase
KR101007790B1 (ko) * 2001-08-10 2011-01-14 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 트레할로오스 또는 말티톨과 금속 이온 화합물과의 회합물(會合物)
GB2379390B (en) 2001-09-11 2005-01-26 Caretek Medical Ltd A novel drug delivery technology
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
MXPA06004489A (es) * 2003-10-23 2006-06-20 Otsuka Pharma Co Ltd Formulacion y metodo de aripiprazol inyectable esteril de liberacion controlada.
FR2873386B1 (fr) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa Composition vaccinale contre le rhodococcus equi
US20060045891A1 (en) * 2004-08-24 2006-03-02 Lovalenti Phillip M Density-matched suspension vehicles and pharmaceutical suspensions
US20060142630A1 (en) * 2004-12-29 2006-06-29 Attila Meretei Systems and methods for treating a thrombus in a blood vessel
US7515971B1 (en) * 2005-09-09 2009-04-07 Pacesetter, Inc. Left atrial pressure sensor lead
GB2430880A (en) * 2005-10-04 2007-04-11 Cambridge Biostability Ltd Pharmaceutical compositions stabilized in glassy particles
GB0523638D0 (en) * 2005-11-21 2005-12-28 Cambridge Biostability Ltd Pharmaceutical device for the administration of substances to patients
US8946200B2 (en) 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
DE102006056790B3 (de) * 2006-12-01 2008-01-17 IfP Privates Institut für Produktqualität GmbH Laboreinmalartikel für Analyse und Diagnosik
EP1930396B1 (de) * 2006-12-04 2011-07-06 Merck Patent GmbH Furochromanderivate
US20090022727A1 (en) 2007-01-26 2009-01-22 Alza Corp. Injectable, nonaqueous suspension with high concentration of therapeutic agent
PT2170279T (pt) * 2007-07-31 2018-04-06 Otsuka Pharma Co Ltd Métodos para produção de suspensão de aripiprazole e formulação liofilizada
EP2254554A1 (en) * 2008-02-25 2010-12-01 Novavax, Inc. Sugar glassified virus like particles (vlps)
US8404850B2 (en) 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
US8722706B2 (en) 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
WO2011007327A2 (en) * 2009-07-16 2011-01-20 Koninklijke Philips Electronics N.V. Suspension for therapeutic use and device for delivering said suspension
US8293299B2 (en) 2009-09-11 2012-10-23 Kraft Foods Global Brands Llc Containers and methods for dispensing multiple doses of a concentrated liquid, and shelf stable Concentrated liquids
CN102115737B (zh) * 2009-12-31 2015-06-03 深圳迈瑞生物医疗电子股份有限公司 稳定碱性磷酸酶或其标记物的试剂和方法
US9028873B2 (en) 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
CN102269761A (zh) 2010-06-04 2011-12-07 深圳迈瑞生物医疗电子股份有限公司 一种碱性磷酸酶结合物的合成工艺
CN102269762B (zh) 2010-06-04 2014-12-10 深圳迈瑞生物医疗电子股份有限公司 结合物的制备方法及相关试剂盒
US20120222979A1 (en) 2011-03-04 2012-09-06 Elwha LLC, a limited liability company of the State of Delaware Glassy compositions
KR102166963B1 (ko) 2011-09-09 2020-10-16 크래프트 푸즈 그룹 브랜즈 엘엘씨 저장 안정성을 갖는 우려낸 음료 농축물 및 그의 제조 방법
IN2014CN03555A (enExample) 2011-10-25 2015-07-03 Onclave Therapeutics Ltd
US11013248B2 (en) 2012-05-25 2021-05-25 Kraft Foods Group Brands Llc Shelf stable, concentrated, liquid flavorings and methods of preparing beverages with the concentrated liquid flavorings
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
CA2953828C (en) 2014-07-03 2022-08-23 Kraft Foods Group Brands Llc Low water coffee and tea beverage concentrates and methods for making the same
CN111558046A (zh) * 2020-05-27 2020-08-21 华润昂德生物药业有限公司 海藻糖在制备重组人促红素液体制剂中的应用及重组人促红素液体制剂、制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031255A (en) * 1975-07-03 1977-06-21 General Foods Corporation Fixing acetaldehyde in sucrose
US3970765A (en) * 1975-07-03 1976-07-20 General Foods Corporation Method for producing sucrose fixed volatile flavors
GB1490814A (en) * 1975-07-22 1977-11-02 Cadbury Ltd Heat-resistant chocolate product and method of manufacturing same
JPS562908A (en) * 1979-06-20 1981-01-13 Nikken Kagaku Kk Preparation of stable live bacterial pharmaceutical remedy
DE3484584D1 (de) * 1983-10-14 1991-06-20 Sumitomo Pharma Injektionen mit verzoegerter abgabe.
WO1989003671A1 (fr) * 1987-10-29 1989-05-05 Dainippon Pharmaceutical Co., Ltd. Preparation a liberation entretenue
US5250429A (en) * 1991-09-20 1993-10-05 Pharmacia P-L Biochemicals Inc. Glassified restriction enzymes
US5424289A (en) * 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
DE69531992T2 (de) 1994-08-04 2004-07-22 Elan Drug Delivery Ltd., Ruddington Feste verabreichungssysteme zur gesteuerten freisetzung von darin eingebauten molekülen sowie verfahren zu deren herstellung
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5593824A (en) * 1994-09-02 1997-01-14 Pharmacia Biotech, Inc. Biological reagent spheres
GB9508691D0 (en) * 1995-04-28 1995-06-14 Pafra Ltd Stable compositions
CA2223438C (en) 1995-06-07 2008-05-13 Quadrant Holdings Cambridge Limited Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby
US5958455A (en) 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
US5762961A (en) 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US5766520A (en) 1996-07-15 1998-06-16 Universal Preservation Technologies, Inc. Preservation by foam formation

Also Published As

Publication number Publication date
EA199900835A1 (ru) 2000-04-24
CN1256626A (zh) 2000-06-14
US6669963B1 (en) 2003-12-30
NO994508D0 (no) 1999-09-17
EP1007000B1 (en) 2006-05-10
EP1007000A2 (en) 2000-06-14
NZ337666A (en) 2001-04-27
CA2293682C (en) 2007-01-16
ATE325605T1 (de) 2006-06-15
JP2002504090A (ja) 2002-02-05
GB9705588D0 (en) 1997-05-07
WO1998041188A2 (en) 1998-09-24
NO994508L (no) 1999-11-17
DE69834495T2 (de) 2006-09-07
AU722627B2 (en) 2000-08-10
CA2293682A1 (en) 1998-09-24
AU6510198A (en) 1998-10-12
DE69834495D1 (de) 2006-06-14
WO1998041188A3 (en) 1998-12-10
EA001873B1 (ru) 2001-10-22

Similar Documents

Publication Publication Date Title
BR9808920A (pt) Partìcula estável em formulações lìquidas
IL96276A0 (en) Transdermal delivery system of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole
NZ336594A (en) Formulation for inhalation which includes a carrier (lactose, glucose, raffinose, melezitose, lactitol, trehalose, sucrose, mannitol or starch
TW224428B (enExample)
AU5936400A (en) Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
CA2024291A1 (en) Dosage device and preparation and use thereof
WO2003041690A3 (en) Three-dimensional suspension printing of dosage forms
HUP0001442A3 (en) Sulfonamide derivatives and pharmaceutical compositions containing them for the treatment of endothelin-mediated disorders
AU3838989A (en) Improved herbicide formulations container silicone surfactant and their uses
HU9201937D0 (en) Aryl ethers, process for their production, and for the production of medical preparations containing them as active agents
NZ336593A (en) Formulation comprising finely divided formoterol and a carrier (lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol or starch
AU2002327097A1 (en) Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient
MX9606391A (es) Preparacion farmaceutica con una sustancia activa hidrofobica y un sistema efervecente, y proceso para preparar la misma.
PT1017392E (pt) Formulacao de medicamento com libertacao controlada do principio activo
BR0008713A (pt) Processos para preparar formulações ecomposições farmacêuticas orais com ecb
NZ336595A (en) Formulation for inhalation comprising finely divided terbutaline sulphate and a carrier (lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol or starch)
MXPA03008061A (es) Composiciones desodorantes y antitranspirantes anhidras que contienen un agente dermoactivo solido soluble en agua y glicerina.
NO20004816L (no) Ny farmasøytisk formulering
EP0435632A3 (en) Phenylpyrimidine derivatives, process for preparing the same, liquid crystal compositions containing said derivatives as active ingredient, and liquid crystal elements using such compositions
HU908294D0 (en) Fungicide preparations containing pyridyl-cyclopropane as active agent and process for the preparation of the active agents
IL152751A0 (en) Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
ZA87500B (en) Symmetrical o-substituted dioximes of benzo-fused beta-diketocycloalkylenes,the processes for their preparation and their application as drugs
HK2794A (en) 8a-acylaminoergoline, its preparation and pharmaceutical compositions containing it
FR2657258B1 (enExample)
AU2506188A (en) Azelastine embonate, processes for its preparation and pharmaceutical formulations which contain azelastine embonate as active substance

Legal Events

Date Code Title Description
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1891 DE 03/04/2007.